Search peptides — top sellers first
Search peptides — top sellers first
Search peptides — top sellers first
GLP receptor-targeting research peptide, supplied for laboratory study only.
Made in USA — Synthesized in our cGMP-compliant US facility
Buy 1, Get 1 Free · auto-applied
Add 2+ items to cart to activate the discount
Secure, encrypted checkout
Frequently bought together
Researchers usually add these to complete the protocol.
BAC Water · 3ml
Essential · extras
GHK-CU · 50mg
recovery
Melanotan 2 · 10mg
Tanning
GLP-3-RT · 24mg
Certificate of analysis
We don't publish a brand-wide spec sheet and call it a “COA.” The certificate you receive references the actual lot number stamped on your vial — with the raw chromatograms attached.
Freedom Diagnostics
Independent analytical lab
Certificate of Analysis
RESULT · PASS
Analytical results
HPLC Chromatogram
Main peak 99.82% · other 0.18%
Alex Johnson
Principal Chemist
Scanned 36×
Know your compound
GLP-3-RT is a synthetic research peptide supplied as a lyophilised powder for reconstitution by qualified researchers. It is provided strictly for laboratory research use only.
Peptides in the incretin / GLP receptor class are studied preclinically for their roles in metabolic signalling pathways. GLP-3-RT is offered to support in-vitro and non-human research in this area.
For research use only — not for human or veterinary use.
The research
The published findings behind this compound — the headline numbers, in plain terms, each cited to source. Preclinical results are directional (animal / in-vitro) and shown for context, not as therapeutic claims.
In a phase 2 trial, participants lost about a quarter of their body weight over 48 weeks - and the more they took, the more they lost.
Reported weight loss scaled with dose across the trial arms.
On the top dose, almost every participant lost at least 10% of their body weight.
Each dot is about 2% of participants; roughly 83% reached at least 15%.
Weight was still dropping at week 48 - the curve had not leveled off when the trial ended.
Relative body weight (baseline = 100); the treated curve had not plateaued by week 48.
In people with type 2 diabetes, a large drop in HbA1c - the standard long-term blood-sugar marker.
Reported HbA1c reductions up to about 2.0% at the higher doses.
In the higher-dose groups, liver fat was nearly cleared - most reached a normal level.
liver-fat reduction
A high proportion reached normal liver fat (under 5%) in the higher-dose arms.
From lab discovery to four phase-2 human trials in just two years.
2022
Discovery (LY3437943)
2023
Obesity phase 2
2023
T2D phase 2
2024
MASLD phase 2
Illustrative timeline drawn from the cited literature.
Mechanism
A triple-incretin research peptide studied for engaging three metabolic receptors at once.
Glucagon-like peptide-1 signalling is studied for glucose-dependent insulin release and appetite regulation.
Glucose-dependent insulinotropic polypeptide is investigated for insulin sensitivity and nutrient handling.
Glucagon-receptor activity is researched for its influence on energy expenditure and hepatic lipid metabolism.
For research use only. Mechanisms described reflect published research literature.
The process
Synthesized
Produced under controlled manufacturing with documented, repeatable processes.
HPLC purity
An independent lab reports the exact purity of every lot — a number, never a 'passes'.
Mass-spec identity
Molecular weight confirms the exact sequence is what the label says.
COA published
The certificate is posted to the open library, by lot, before the vial ships.
Best sellers
FAQ
Common questions about GLP-3-RT
The COA guarantee
Have any lot independently re-tested. If the results don't match the published certificate, we refund the order in full — no returns, no questions.
Order with coverThird-party tested
An independent, accredited lab — no commercial interest in the result.
A COA on every lot
A lot-specific certificate ships with each vial, archived by batch.
Test it yourself → refund
Re-test any batch at any lab. A mismatch is a full refund.
